CRISPR-Cas9 is a widely used technology for the editing of genetic sequences. Thermo Fisher Scientific seeks approaches or technologies to improve the effectiveness of this powerful tool.
Thermo Fisher Scientific is seeking partners and opportunities to develop and commercialize improvements to existing genome editing technology and workflows. CRISPR-Cas9 has emerged as an easy-to-use technology and has quickly become the standard for genome editing, but it has some acknowledged limitations. We are therefore seeking new improvements to the Cas9 system that:
The successful technology improvement should increase the efficiency and/or reduce the off-target effects of the system. Additionally, the successful technology should be backed by performance–benchmarking data against currently available methods in mammalian cells, utilizing commercially available reagents from market-leading companies including
Thermo Fisher Scientific.
Please note that only nonconfidential information can be accepted. By submitting a response, you confirm that the response does not contain any confidential information.